PMEL and melanoma: In a phase III randomized controlled trial involving the administration of ipilimumab either alone or in conjunction with a glycoprotein 100 (gp100) peptide vaccine derived from melanoma, patients who received both ipilimumab and gp100 exhibited a median objective survival (OS) of 10.0 months, compared to 6.4 months for those solely receiving gp100.